Rare but not forgotten: Therapeutic advancements for rare childhood cancers

Area of Science:

• Pediatric Oncology
• Rare Cancers
• Cancer Therapeutics

Background:

• Pediatric cancers constitute less than 1% of all new cancer cases.
• Certain pediatric cancers are exceptionally rare, posing unique research and treatment challenges.
• Advances in multi-institutional trials and collaborative efforts have spurred progress in treating rare pediatric malignancies.

Purpose of the Study:

• To review recent therapeutic advances in rare pediatric cancers.
• To highlight the role of immunotherapies, molecularly targeted therapies, and radioligands.
• To discuss challenges and future directions in rare pediatric cancer research.

Main Methods:

• Review of recent multi-institutional pediatric clinical trials.
• Analysis of FDA approvals for novel cancer treatments in pediatric populations.
• Integration of data from adult studies relevant to pediatric rare cancers.

Main Results:

• FDA approvals of immune checkpoint inhibitors for multiple rare pediatric tumor types.
• NTRK inhibitors (larotrectinib, entrectinib, repotrectinib) approved for pediatric solid tumors with NTRK fusions.
• ALK inhibitor (crizotinib) and radioligand (LUATHERA) approvals for specific rare pediatric and adolescent/adult tumors.

Conclusions:

• Significant progress has been made in treating rare pediatric cancers through novel therapies.
• Challenges remain, including limited patient cohorts for clinical trials and insufficient financial incentives.
• Continued coordinated efforts are crucial for developing new treatments and improving outcomes for children with rare cancers.